Stock listing
Frankfurt:7VR Celcuity Inc. Aktie
German listing (Frankfurt) of Celcuity Inc. · home listing NASDAQ:CELC
Follow Celcuity Inc. into a list and get an email when it puts out news.
Home listing price · NASDAQ:CELC
$53.35 USD -2.25 (-4.0%)
Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:CELC
- Day range
- $53.20 – $57.00 USDNov 20, 2026
- Volume
- 636,527 sharesNov 20, 2026
- Market cap
- $2.62B USDAt the close on Nov 20, 2026 · price × 49.13M shares outstanding
- 52-week range
- $53.20 – $151.02 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $87.38M USDMedian day 940,700 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:CELC · Home | $53.35 USD | -2.25 (-4.0%) | 636,527 | $55.02 | $57.00 | $53.20 | $55.60 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:CELC · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $53.35 | -2.25 | -4.0% | $55.02 | $57.00 | $53.20 | 636,527 | |
| $55.60 | -2.41 | -4.2% | $57.62 | $58.12 | $55.48 | 984,323 | |
| $58.01 | -2.56 | -4.2% | $60.21 | $60.97 | $56.64 | 2,208,362 | |
| $60.57 | -3.80 | -5.9% | $63.84 | $64.87 | $60.40 | 730,848 | |
| $64.37 | +0.20 | +0.3% | $64.20 | $64.60 | $61.71 | 646,495 | |
| $64.17 | -0.15 | -0.2% | $63.36 | $65.81 | $60.97 | 906,766 | |
| $64.32 | -2.73 | -4.1% | $67.91 | $67.95 | $64.27 | 696,780 | |
| $67.05 | -3.32 | -4.7% | $68.96 | $71.00 | $66.20 | 769,793 | |
| $70.37 | +3.58 | +5.4% | $67.79 | $72.24 | $66.40 | 921,953 | |
| $66.79 | +2.75 | +4.3% | $67.15 | $67.27 | $62.44 | 1,052,504 | |
| $64.04 | -5.20 | -7.5% | $68.28 | $68.77 | $63.44 | 1,423,629 | |
| $69.24 | -0.48 | -0.7% | $72.00 | $72.00 | $67.48 | 1,188,639 | |
| $69.72 | +2.65 | +4.0% | $67.13 | $70.99 | $67.00 | 1,105,548 | |
| $67.07 | -2.06 | -3.0% | $69.50 | $70.13 | $66.20 | 770,521 | |
| $69.13 | -0.17 | -0.2% | $68.47 | $70.43 | $67.42 | 700,079 | |
| $69.30 | -0.16 | -0.2% | $70.66 | $73.29 | $69.00 | 819,605 | |
| $69.46 | +1.39 | +2.0% | $67.41 | $69.95 | $67.39 | 1,125,891 | |
| $68.07 | +2.27 | +3.4% | $66.08 | $68.81 | $65.69 | 885,824 | |
| $65.80 | +0.55 | +0.8% | $65.50 | $68.39 | $64.92 | 1,866,245 | |
| $65.25 | -0.32 | -0.5% | $65.57 | $66.30 | $63.49 | 1,316,079 | |
| $65.57 | +4.01 | +6.5% | $61.74 | $66.93 | $61.74 | 1,932,805 | |
| $61.56 | +1.56 | +2.6% | $60.42 | $62.84 | $60.15 | 1,590,636 | |
| $60.00 | +2.88 | +5.0% | $57.12 | $62.56 | $56.81 | 2,382,968 | |
| $57.12 | +0.54 | +1.0% | $58.19 | $59.49 | $56.60 | 2,669,091 | |
| $56.58 | -3.72 | -6.2% | $60.16 | $60.23 | $53.54 | 4,338,300 | |
| $60.30 | +0.40 | +0.7% | $60.67 | $61.73 | $60.00 | 2,123,400 | |
| $59.90 | -3.29 | -5.2% | $62.60 | $63.44 | $58.98 | 2,441,300 | |
| $63.19 | -2.66 | -4.0% | $65.17 | $65.69 | $62.86 | 1,497,800 | |
| $65.85 | -2.09 | -3.1% | $67.40 | $67.52 | $65.03 | 1,050,100 | |
| $67.94 | +0.07 | +0.1% | $67.78 | $68.53 | $66.91 | 1,277,700 | |
| $67.87 | +2.09 | +3.2% | $64.74 | $69.08 | $63.23 | 2,590,800 | |
| $65.78 | -5.47 | -7.7% | $70.52 | $73.51 | $64.15 | 3,156,300 | |
| $71.25 | -2.37 | -3.2% | $74.28 | $76.29 | $70.32 | 1,563,200 | |
| $73.62 | +1.52 | +2.1% | $72.71 | $74.60 | $69.00 | 1,718,400 | |
| $72.10 | -3.03 | -4.0% | $75.21 | $75.44 | $70.68 | 1,421,100 | |
| $75.13 | -4.39 | -5.5% | $78.38 | $79.18 | $75.00 | 1,096,800 | |
| $79.52 | +2.14 | +2.8% | $81.30 | $88.68 | $77.84 | 2,555,300 | |
| $77.38 | -2.26 | -2.8% | $79.64 | $80.52 | $77.25 | 1,221,600 | |
| $79.64 | +0.12 | +0.2% | $79.44 | $80.02 | $77.09 | 610,400 | |
| $79.52 | +0.15 | +0.2% | $80.00 | $80.28 | $78.02 | 657,200 | |
| $79.37 | -0.62 | -0.8% | $79.73 | $80.19 | $77.07 | 1,237,700 | |
| $79.99 | -4.11 | -4.9% | $84.93 | $85.05 | $79.40 | 739,300 | |
| $84.10 | +0.10 | +0.1% | $84.00 | $85.50 | $82.80 | 540,200 | |
| $84.00 | +3.39 | +4.2% | $81.37 | $84.33 | $80.26 | 718,100 | |
| $80.61 | -4.30 | -5.1% | $84.89 | $85.17 | $79.77 | 1,406,100 | |
| $84.91 | +2.33 | +2.8% | $85.22 | $87.50 | $84.41 | 692,100 | |
| $82.58 | -0.12 | -0.1% | $83.33 | $84.07 | $81.54 | 799,300 | |
| $82.70 | -0.83 | -1.0% | $83.65 | $83.65 | $80.62 | 783,500 | |
| $83.53 | +0.08 | +0.1% | $83.45 | $84.91 | $82.49 | 1,645,900 | |
| $83.45 | -2.04 | -2.4% | $86.38 | $87.01 | $83.24 | 863,400 | |
| $85.49 | -4.59 | -5.1% | $88.37 | $89.48 | $84.82 | 1,069,400 | |
| $90.08 | -2.94 | -3.2% | $92.00 | $93.80 | $90.00 | 708,300 | |
| $93.02 | -2.68 | -2.8% | $93.62 | $97.43 | $92.61 | 940,700 | |
| $95.70 | -0.73 | -0.8% | $95.83 | $97.25 | $94.55 | 515,500 | |
| $96.43 | +0.23 | +0.2% | $97.11 | $98.00 | $94.92 | 773,200 | |
| $96.20 | +4.22 | +4.6% | $93.61 | $96.94 | $92.13 | 818,200 | |
| $91.98 | +2.92 | +3.3% | $89.00 | $92.85 | $88.64 | 1,161,800 | |
| $89.06 | +0.62 | +0.7% | $87.61 | $89.81 | $86.99 | 819,000 | |
| $88.44 | -4.80 | -5.1% | $91.90 | $92.48 | $88.23 | 610,300 | |
| $93.24 | -1.84 | -1.9% | $95.06 | $95.06 | $92.54 | 457,300 | |
| $95.08 | +2.81 | +3.0% | $92.38 | $96.16 | $91.02 | 655,400 | |
| $92.27 | +1.48 | +1.6% | $92.47 | $94.33 | $91.68 | 681,600 | |
| $90.79 | -2.74 | -2.9% | $93.47 | $93.47 | $90.75 | 514,107 | |
| $93.53 | +2.96 | +3.3% | $91.39 | $95.46 | $90.51 | 889,300 | |
| $90.57 | -3.08 | -3.3% | $92.90 | $93.36 | $90.26 | 936,900 |
- Ticker
- Frankfurt:7VR
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- Frankfurt
- Currency
- EUR
What changed lately
Latest news release · Nov 9, 2026
Celcuity Announces FDA Acceptance of sNDA for REVTORPYK™ (gedatolisib) for HR+/HER2-, PIK3CA Mutant Locally Advanced or Metastatic Breast Cancer
Latest earnings call · Nov 5, 2026
Celcuity (NASDAQ:CELC) Q3 2026 Earnings Call
Replay and transcript
Latest deck · August 2026
Investor Presentation (August 2026)
Investor deck · 54 slides
Latest news
Celcuity Announces FDA Acceptance of sNDA for REVTORPYK™ (gedatolisib) for HR+/HER2-, PIK3CA Mutant Locally Advanced or Metastatic Breast Cancer
Nov 9, 2026
Closed $70.37 (+5.4%) on Nov 9, 2026
Celcuity Inc. Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Nov 5, 2026
Closed $66.79 (+4.3%) on Nov 6, 2026
Celcuity To Participate in Upcoming Investor Conferences
Nov 3, 2026
Closed $69.72 (+4.0%) on Nov 3, 2026
Celcuity Schedules Release of Third Quarter 2026 Financial Results and Webcast/Conference Call
Oct 29, 2026
Closed $69.30 (-0.2%) on Oct 29, 2026
Celcuity Presents Updated Results from the PIK3CA MT Cohort of the Phase 3 VIKTORIA-1 Study in Patients with HR+/HER2- Advanced Breast Cancer at the ESMO Congress 2026
Oct 24, 2026
Closed $65.80 (+0.8%) on Oct 26, 2026
Celcuity Presents Updated Data from a Phase 1b/2 Study Evaluating Gedatolisib Plus Darolutamide in Men with Metastatic Castration-Resistant Prostate Cancer at the ESMO Congress 2026
Oct 23, 2026
Closed $65.25 (-0.5%) on Oct 23, 2026
Celcuity Appoints David Gryska to Its Board of Directors
Oct 5, 2026
Closed $73.62 (+2.1%) on Oct 5, 2026
Celcuity Announces Multiple Presentations At The European Society For Medical Oncology (ESMO) Congress 2026
Oct 5, 2026
Closed $73.62 (+2.1%) on Oct 5, 2026
Celcuity Announces That REVTORPYK™ (gedatolisib) Is Now Commercially Available In The United States
Sep 30, 2026
Closed $79.52 (+2.8%) on Sep 30, 2026
Celcuity Inc. Reports Release of Second Quarter 2026 Financial Results and Provides Corporate Update
Aug 13, 2026
Closed $92.00 (+6.2%) on Aug 14, 2026
Celcuity Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 32 in the last 12 months · 167 in all · newest Nov 9, 2026 · oldest 2019
- Calls
- 25 calls with a replay · 25 with a transcript · latest Nov 5, 2026
- Decks
- 36 decks · latest August 2026
Where Celcuity Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:CELC · Home listing | NASDAQ | United States | USD |
| BOATS:CELC | BOATS | United States | USD |
| gettex:7VR | gettex | Germany | EUR |
| Tradegate:7VR | Tradegate | Germany | EUR |
| Frankfurt:7VR · This page | Frankfurt | Germany | EUR |
| Munich:7VR | Munich | Germany | EUR |
| Dusseldorf:7VR | Dusseldorf | Germany | EUR |
| Hamburg:7VR | Hamburg | Germany | EUR |
| Hanover:7VR | Hanover | Germany | EUR |
| Lang & Schwarz:A2JAAX | Lang & Schwarz | Germany | EUR |
| LS Exchange:A2JAAX | LS Exchange | Germany | EUR |
| Xetra:7VR | Xetra | Germany | EUR |
Valuation
Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $1.98B USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- Negative EBITDA
- Price/book
- Negative equity
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- Negative equity
- Beta vs S&P 500
- 1.10
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Celcuity Inc. · NASDAQ:CELC | US$2.62B | US$1.98B | n/a | n/a | n/a | n/a | n/a | n/a | 1.10 |
| Dyne Therapeutics, Inc. · NASDAQ:DYN | US$2.90B | US$1.97B | n/a | n/a | n/a | 3.1× | n/a | 0.2× | 1.51 |
| Shanghai Junshi Biosciences Co., Ltd. Class A · SSE:688180 | US$2.88B | US$2.99B | n/a | 8.0× | n/a | 3.2× | −35.0% | 0.7× | n/a |
| SELLAS Life Sciences Group, Inc. · NASDAQ:SLS | US$2.78B | US$2.65B | n/a | n/a | n/a | 21.1× | n/a | 0.0× | 2.19 |
| HLB Co., Ltd. · KRX:028300 | US$2.69B | US$2.69B | n/a | 36.9× | n/a | 10.4× | −219.1% | 0.2× | n/a |
| Zai Lab Ltd. · HKEX:9688 | US$2.60B | US$2.04B | n/a | 4.6× | n/a | 4.6× | −44.9% | 0.0× | n/a |
| Xencor, Inc. · NASDAQ:XNCR | US$2.50B | US$2.16B | n/a | 10.8× | n/a | 4.5× | −58.8% | 0.1× | 1.21 |
| IDEAYA Biosciences, Inc. · NASDAQ:IDYA | US$2.47B | US$1.66B | n/a | 45.5× | n/a | 2.3× | n/a | 0.0× | 0.96 |
| MBX Biosciences, Inc. · NASDAQ:MBX | US$2.46B | US$1.98B | n/a | n/a | n/a | 5.2× | n/a | 0.0× | 1.30 |
| Almirall SA · BME:ALM | US$2.45B | US$2.46B | 31.1× | 1.6× | 7.3× | 1.5× | 5.1% | 0.2× | n/a |
| Keymed Biosciences, Inc. · HKEX:2162 | US$2.43B | US$2.04B | n/a | 19.6× | n/a | 4.0× | −73.0% | 0.2× | n/a |
| Median of the others | US$2.55B | US$2.10B | 31.1× | 10.8× | 7.3× | 4.3× | −51.8% | 0.1× | 1.30 |
Forecasts
10 strong buy · 3 buy · Analysts' consensus from EODHD, read Nov 20, 2026. Not 6ix's view and not investment advice.
- Price target
- 150.85 USD · Analysts' mean
- EPS, year to Dec 2026
- -4.28 · 2 analysts
- Revenue, year to Dec 2026
- 13.64M · 11 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Brian Sullivan | Chief Executive Officer & Co-founder |
| Vicky Hahne | Chief Financial Officer |
| Brent Eilefson | General Counsel and Chief Compliance Officer |
| Byron Robinson | Chief Strategy Officer |
| Eldon Mayer | Chief Commercial Officer |
| Igor Gorbatchevsky | Chief Medical Officer |
| Lance Laing | Chief Science Officer & Co-founder |
Board
| Director | Role |
|---|---|
| Charles R. Romp | Director |
| David F. Dalvey | Director |
| David W. Gryska | Director |
| Leo Furcht | Director |
| Polly Murphy | Director |
| Richard Buller | Director |
| Richard J. Nigon | Director |
Events
Calls
| Call | When | Status |
|---|---|---|
| Celcuity (NASDAQ:CELC) Q3 2026 Earnings Call | Thu, Nov 05, 2026 · 4:30 PM ET | Replay |
| Celcuity (NASDAQ:CELC) Q2 2026 Earnings Call | Thu, Aug 13, 2026 · 4:30 PM ET | Replay |
| Celcuity (NASDAQ:CELC) Q1 2026 Earnings Call | Thu, May 14, 2026 · 4:30 PM ET | Replay |
| Celcuity (NASDAQ:CELC) Q4 2025 Earnings Call | Wed, Mar 25, 2026 · 4:30 PM ET | Replay |
| Celcuity (NASDAQ:CELC) Q3 2025 Earnings Call | Wed, Nov 12, 2025 · 4:30 PM ET | Replay |
| Celcuity (NASDAQ:CELC) Q2 2025 Earnings Call | Thu, Aug 14, 2025 · 4:30 PM ET | Replay |
| Celcuity (NASDAQ:CELC) Q1 2025 Earnings Call | Wed, May 14, 2025 · 4:30 PM ET | Replay |
| Celcuity (NASDAQ:CELC) Q4 2024 Earnings Call | Mon, Mar 31, 2025 · 4:30 PM ET | Replay |
| Celcuity (NASDAQ:CELC) Q3 2024 Earnings Call | Thu, Nov 14, 2024 · 4:30 PM ET | Replay |
| Celcuity (NASDAQ:CELC) Q2 2024 Earnings Call | Wed, Aug 14, 2024 · 4:30 PM ET | Replay |
All 25 calls
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 5, 2026 · After close | +4.3% |
| Q2 2026 | Aug 13, 2026 · After close | +6.2% |
| Q1 2026 | May 14, 2026 · After close | +2.2% |
| Q4 2025 | Mar 19, 2026 | −5.8% |
| Q3 2025 | Nov 12, 2025 · After close | +1.0% |
| Q2 2025 | Aug 14, 2025 · After close | −0.2% |
| Q1 2025 | May 14, 2025 · After close | −3.1% |
| Q4 2024 | Mar 25, 2025 · Before open | −3.0% |
| Q3 2024 | Nov 14, 2024 · After close | −10.3% |
| Q2 2024 | Aug 14, 2024 · After close | −3.4% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 15, 2024 · After close | +2.5% |
| Q4 2023 | Mar 27, 2024 · After close | +18.9% |
| Q3 2023 | Nov 13, 2023 · Before open | +1.1% |
| Q2 2023 | Aug 10, 2023 · After close | −1.1% |
| Q1 2023 | May 15, 2023 · After close | +3.0% |
| Q4 2022 | Mar 23, 2023 · After close | −5.5% |
| Q3 2022 | Nov 10, 2022 · After close | +3.5% |
| Q2 2022 | Aug 11, 2022 · After close | −2.3% |
| Q1 2022 | May 16, 2022 · After close | −2.8% |
| Q4 2021 | Mar 23, 2022 · After close | −1.0% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (August 2026) | Investor deck | 54 slides | August 2026 |
| Corporate Update (July 2026) | Corporate update | 22 slides | Jul 15, 2026 |
| Corporate Update (July 2026) | Corporate update | 21 slides | Jul 15, 2026 |
| ASCO 2026 Annual Meeting | Conference | 19 slides | Jun 2, 2026 |
| Investor Conference Call (June 2026) | Conference | 39 slides | Jun 2, 2026 |
| 2025 San Antonio Breast Cancer Symposium (SABCS) | Conference | 18 slides | Dec 11, 2025 |
| Investor Presentation (November 2025) | Investor deck | 54 slides | November 2025 |
| Technical Presentation (October 2025) | Technical | 22 slides | Oct 20, 2025 |
| Technical Presentation (October 2025) | Technical | 18 slides | Oct 18, 2025 |
| Investor Presentation (October 2025) | Investor deck | 54 slides | October 2025 |
All 36 decks
Financings
| Raise | Date |
|---|---|
| 2.750% convertible senior notes due 2031 Made bigger: US$175M · Jefferies +4 Dealers: Jefferies (co-lead), TD Cowen (co-lead), Leerink Partners (co-lead), LifeSci Capital, ICR Capital LLC Use of proceeds: Working capital and general corporate purposes, including clinical trials, commercial launch, R&D, capital expenditures and business development | Jul 30, 2025 |
| Public offering of common stock and pre-funded warrants Update: US$75M · US$38 a share · Jefferies +3 Dealers: Jefferies (co-lead), TD Cowen (co-lead), Leerink Partners (co-lead), LifeSci Capital Use of proceeds: Working capital and general corporate purposes, including clinical trials, commercial launch, R&D, capital expenditures and business development | Jul 30, 2025 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Priced at US$9.50 a share on Sep 19, 2017.
- Price
- US$9.50 a share
- Shares offered
- 2,400,000 shares of common stock
- Offering size
- US$22.8 million
- Underwriters' option
- Up to 360,000 more shares
- Listing
- CELC on the Nasdaq Capital Market
- Underwriter
- Craig-Hallum Capital Group
- Shares delivered
- On or about Sep 22, 2017
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Jun 12, 2017 |
| Filed publicly | Aug 23, 2017 |
| Amended 3 times | Newest Sep 12, 2017 |
| Shares registered with an exchange | Sep 15, 2017 |
| Declared effective by the SEC | Sep 19, 2017 |
| Final prospectus, with the price | Sep 20, 2017 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Sep 20, 2017 |
| EFFECT · Notice that a registration is effective | Sep 19, 2017 |
| S-1MEF · Registration of more shares for the same offering | Sep 19, 2017 |
| CERTNAS · Nasdaq's certificate of listing | Sep 19, 2017 |
| CORRESP · Letter to the SEC | Sep 18, 2017 |
| CORRESP · Letter to the SEC | Sep 18, 2017 |
| 8-A12B · Registration of shares for listing on an exchange | Sep 15, 2017 |
| CORRESP · Letter to the SEC | Sep 14, 2017 |
| CORRESP · Letter to the SEC | Sep 14, 2017 |
| S-1/A · Registration statement, amended | Sep 12, 2017 |
All 24 filings
| Filing | Filed |
|---|---|
| S-1/A · Registration statement, amended | Sep 7, 2017 |
| CORRESP · Letter to the SEC | Sep 5, 2017 |
| CORRESP · Letter to the SEC | Sep 1, 2017 |
| S-1/A · Registration statement, amended | Sep 1, 2017 |
| CORRESP · Letter to the SEC | Aug 31, 2017 |
| S-1 · Registration statement | Aug 23, 2017 |
| UPLOAD · Letter from the SEC | Aug 23, 2017 |
| DRSLTR · Letter to the SEC with a draft | Aug 14, 2017 |
| DRS/A · Draft registration statement, amended | Aug 14, 2017 |
| UPLOAD · Letter from the SEC | Jul 26, 2017 |
| DRSLTR · Letter to the SEC with a draft | Jul 14, 2017 |
| DRS/A · Draft registration statement, amended | Jul 14, 2017 |
| UPLOAD · Letter from the SEC | Jul 6, 2017 |
| DRS · Draft registration statement | Jun 12, 2017 |
Open IPO · From the cover of the final prospectus (424B4) filed Sep 20, 2017
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 154.0K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of revenue | 167.0K | 129.9K | 142.8K | 210.9K | 303.2K | 385.6K | 339.0K | 223.0K | 104.7K | 73.1K |
| Gross profit | -167.0K | -129.9K | -142.8K | -210.9K | -303.2K | -385.6K | -339.0K | -223.0K | -104.7K | -73.1K |
| Research and development | 145.0M | 104.2M | 60.6M | 35.3M | 25.8M | 7.68M | 6.27M | 6.33M | 4.98M | 3.06M |
| Selling, general and administrative | 27.2M | 9.06M | 5.64M | 4.10M | 2.60M | 1.87M | 1.54M | 1.61M | 972.5K | 263.7K |
| Operating income | -172.2M | -113.3M | -66.2M | -39.4M | -28.4M | -9.56M | -7.81M | -7.93M | -5.95M | -3.33M |
| Depreciation and amortization | 167.0K | 130.0K | 142.8K | 210.9K | 303.2K | 385.6K | 339.0K | 223.0K | 104.7K | 73.1K |
| EBITDA | -172.0M | -113.1M | -66.1M | -39.2M | -28.1M | -9.17M | -7.47M | -7.71M | -5.85M | -3.26M |
| Interest expense | 17.1M | 10.3M | 5.33M | 2.11M | 1.26M | 120 | 159 | 111 | 451.7K | 0 |
| Income before tax | -177.0M | -111.8M | -63.8M | -40.4M | -29.6M | -9.47M | -7.36M | -7.48M | -6.25M | -3.31M |
| Income tax | -3 | 978.9K | 959.1K | 0 | 0 | 0 | 0 | 0 | ||
| Net income | -177.0M | -111.8M | -63.8M | -40.4M | -29.6M | -9.47M | -7.36M | -7.48M | -6.25M | -3.31M |
| Earnings per share, basic | -3.79 | -2.83 | -2.69 | -2.64 | -2.21 | -0.92 | -0.72 | -0.74 | -0.84 | -0.52 |
| Earnings per share, diluted | -3.79 | -2.83 | -2.69 | -2.64 | -2.21 | -0.92 | -0.72 | -0.74 | -0.84 | -0.52 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 165.7M | 22.5M | 30.7M | 24.6M | 84.3M | 11.6M | 18.7M | 15.9M | 2.69M | 5.86M |
| Short-term investments | 275.8M | 212.6M | 149.9M | 144.0M | 22 | 22.0K | 0 | 8.95M | 21.6M | 0 |
| Receivables | 1.60M | 805.9K | 203.7K | 298.8K | 190.0K | 190.0K | ||||
| Inventory | -8.63M | -203.7K | -298.8K | -190.0K | -190.0K | 0 | ||||
| Current assets | 465.7M | 244.6M | 190.6M | 175.2M | 85.4M | 12.2M | 19.3M | 25.2M | 24.5M | 5.91M |
| Property, plant and equipment | 499.0K | 336.0K | 228.8K | 260.3K | 312.4K | 558.9K | 833.5K | 813.6K | 280.1K | 144.9K |
| Goodwill | 0 | |||||||||
| Total assets | 466.6M | 245.1M | 191.2M | 175.7M | 85.9M | 13.0M | 20.3M | 26.0M | 32.0M | 6.06M |
| Accounts payable | 6.41M | 9.37M | 5.08M | 2.63M | 1.51M | 217.4K | 142.8K | 119.8K | 71.9K | 331.5K |
| Current liabilities | 44.2M | 31.7M | 14.2M | 6.88M | 2.51M | 1.19M | 911.3K | 662.3K | 578.1K | 445.4K |
| Long-term debt | 321.9M | 97.7M | 37.0M | 35.0M | 14.6M | 0 | ||||
| Total debt | 137.5M | 105.1M | 37.6M | 35.8M | 16.0M | 262.5K | 256.1K | 25.6K | ||
| Total liabilities | 366.0M | 129.5M | 51.5M | 41.9M | 17.2M | 1.25M | 983.2K | 682.2K | 578.1K | 445.4K |
| Shareholders' equity | 100.6M | 115.6M | 139.8M | 133.8M | 68.7M | 11.7M | 19.3M | 25.3M | 31.4M | 5.61M |
| Shares outstanding | 48.2M | 37.1M | 25.5M | 21.7M | 14.9M | 10.3M | 10.3M | 10.2M | 10.1M | 0 |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -153.3M | -83.5M | -53.8M | -36.0M | -20.3M | -7.15M | -6.00M | -6.08M | -4.95M | -2.89M |
| Capital spending | -249.0K | -250.0K | -97.6K | -158.8K | -81.9K | -89.4K | -380.2K | -629.6K | -239.8K | -40.9K |
| Free cash flow | -153.5M | -83.7M | -53.9M | -36.2M | -20.4M | -7.24M | -6.38M | -6.71M | -5.19M | -2.93M |
| Cash from investing | -64.1M | -63.1M | -5.01M | -144.0M | -81.4K | -89.4K | 8.53M | 19.1M | -29.0M | -40.9K |
| Cash from financing | 360.6M | 138.4M | 64.9M | 120.3M | 93.0M | 138.0K | 259.3K | 236.7K | 30.7M | 3.72M |
| Dividends paid | 0 | |||||||||
| Share buybacks | 95.9M | 82.2K | 60.3K | 266.3K | -55.1K | 24.1M | 3.72M | |||
| Change in cash | 143.2M | -8.15M | 6.09M | -59.7M | 72.6M | -7.10M | 2.79M | 13.3M | -3.22M | 789.1K |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 16, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 16, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 5, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 5, 2026 | Results | SEC |
| 4 · Change in ownership | Oct 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 5, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Oct 5, 2026 | Insider trade | SEC |
| 8-K · Current report | Oct 2, 2026 | Management or board change | SEC |
| 8-K · Current report | Sep 30, 2026 | Current report | SEC |
| 8-K · Current report | Aug 26, 2026 | Current report | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Aug 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 18, 2026 | Insider trade | SEC |
| 10-Q · Quarterly report | Aug 13, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 13, 2026 | Results | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 11, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Jul 16, 2026 | Big-stake notice | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Jul 16, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jul 16, 2026 | Insider trade | SEC |
| 8-K/A · Current report, amended | Jul 15, 2026 | Current report | SEC |
| 144 · Notice of proposed sale | Jul 14, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jul 14, 2026 | Other filings | SEC |
| 8-K · Current report | Jul 14, 2026 | Current report | SEC |
| 4 · Change in ownership | Jun 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 9, 2026 | Insider trade | SEC |
| 8-K · Current report | Jun 8, 2026 | Material contract | SEC |
| 424B5 · Prospectus | Jun 5, 2026 | Offer document | SEC |
| 305B2 | Jun 5, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jun 4, 2026 | Insider trade | SEC |
| FWP · Free writing prospectus | Jun 4, 2026 | Offer document | SEC |
| 424B5 · Prospectus | Jun 3, 2026 | Offer document | SEC |
| 8-K · Current report | Jun 2, 2026 | Current report | SEC |
| 4 · Change in ownership | May 20, 2026 | Insider trade | SEC |
| 8-K/A · Current report, amended | May 20, 2026 | Management or board change | SEC |
| S-8 · Registration statement for employee plans | May 18, 2026 | Offer document | SEC |
| 8-K · Current report | May 18, 2026 | Management or board change | SEC |
| SCHEDULE 13G · Big-stake notice | May 15, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | May 14, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 14, 2026 | Results | SEC |
| 4 · Change in ownership | May 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 6, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | May 4, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | May 4, 2026 | Other filings | SEC |
| 8-K · Current report | May 1, 2026 | Current report | SEC |
| 4 · Change in ownership | Apr 13, 2026 | Insider trade | SEC |
| ARS · Annual report to shareholders | Apr 2, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 2, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 2, 2026 | Meeting notice | SEC |
| 4 · Change in ownership | Apr 2, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 31, 2026 | Other filings | SEC |
| 10-K · Annual report | Mar 26, 2026 | Annual report | SEC |
| 8-K · Current report | Mar 25, 2026 | Results | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Mar 24, 2026 | Big-stake notice | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Mar 9, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 17, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 17, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 13, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Feb 13, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 12, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Feb 12, 2026 | Management or board change | SEC |
| 4 · Change in ownership | Jan 29, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jan 27, 2026 | Other filings | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Jan 16, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 9, 2026 | Insider trade | SEC |
| S-3ASR · Registration statement | Jan 9, 2026 | Offer document | SEC |
| 4 · Change in ownership | Dec 9, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 8, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 5, 2025 | Other filings | SEC |
| 4 · Change in ownership | Dec 3, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 1, 2025 | Other filings | SEC |
| 4 · Change in ownership | Nov 24, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 21, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 21, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 20, 2025 | Other filings | SEC |
| 8-K · Current report | Nov 17, 2025 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 13, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 13, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 13, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 12, 2025 | Results | SEC |
| 8-K · Current report | Oct 20, 2025 | Current report | SEC |
| D/A | Sep 23, 2025 | Other filings | SEC |
| 4 · Change in ownership | Sep 15, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 10, 2025 | Insider trade | SEC |
| 8-K · Current report | Sep 10, 2025 | Material contract | SEC |
| 4 · Change in ownership | Sep 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 20, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 20, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 20, 2025 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Aug 18, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Aug 14, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 14, 2025 | Results | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 4, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 4, 2025 | Big-stake notice | SEC |
| 3 · Initial statement of ownership | Aug 1, 2025 | Insider trade | SEC |
| SCHEDULE 13D · Big-stake notice | Aug 1, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Aug 1, 2025 | Material contract | SEC |
| 305B2 | Jul 31, 2025 | Other filings | SEC |
| 8-K · Current report | Jul 31, 2025 | Material contract | SEC |
| 424B5 · Prospectus | Jul 31, 2025 | Offer document | SEC |
| 424B5 · Prospectus | Jul 31, 2025 | Offer document | SEC |
| 4 · Change in ownership | Jul 30, 2025 | Insider trade | SEC |
| FWP · Free writing prospectus | Jul 30, 2025 | Offer document | SEC |
| FWP · Free writing prospectus | Jul 30, 2025 | Offer document | SEC |
| 424B5 · Prospectus | Jul 29, 2025 | Offer document | SEC |
| 8-K · Current report | Jul 29, 2025 | Material contract | SEC |
| 424B5 · Prospectus | Jul 28, 2025 | Offer document | SEC |
| 424B5 · Prospectus | Jul 28, 2025 | Offer document | SEC |
| 144 · Notice of proposed sale | Jul 28, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Jul 28, 2025 | Other filings | SEC |
| 8-K · Current report | Jul 28, 2025 | Current report | SEC |
| 8-K · Current report | Jun 30, 2025 | Current report | SEC |
| S-8 · Registration statement for employee plans | Jun 4, 2025 | Offer document | SEC |
| 4 · Change in ownership | May 29, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 29, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 21, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 21, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 21, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 21, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 21, 2025 | Insider trade | SEC |
| 8-K · Current report | May 16, 2025 | Management or board change | SEC |
| 10-Q · Quarterly report | May 15, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 14, 2025 | Results | SEC |
| 4 · Change in ownership | Apr 15, 2025 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Apr 7, 2025 | Big-stake notice | SEC |
| ARS · Annual report to shareholders | Apr 1, 2025 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 1, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 1, 2025 | Meeting notice | SEC |
| 10-K · Annual report | Mar 31, 2025 | Annual report | SEC |
| 8-K · Current report | Mar 31, 2025 | Results | SEC |
| 4 · Change in ownership | Mar 5, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 18, 2025 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 11, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 4, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 6, 2025 | Insider trade | SEC |
| 8-K · Current report | Dec 6, 2024 | Current report | SEC |
| 424B5 · Prospectus | Dec 6, 2024 | Offer document | SEC |
| 4 · Change in ownership | Dec 3, 2024 | Insider trade | SEC |
| EFFECT · Notice that a registration is effective | Dec 3, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Nov 27, 2024 | Other filings | SEC |
| S-3/A · Registration statement, amended | Nov 26, 2024 | Offer document | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 14, 2024 | Quarterly report | SEC |
| SC 13G · Big-stake notice | Nov 14, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Nov 14, 2024 | Results | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Oct 25, 2024 | Insider trade | SEC |
| D/A | Oct 15, 2024 | Other filings | SEC |
| 8-K · Current report | Oct 9, 2024 | Meeting outcome | SEC |
| SC 13G/A · Big-stake notice, amended | Oct 7, 2024 | Big-stake notice | SEC |
| UPLOAD · Letter from the SEC | Sep 6, 2024 | Other filings | SEC |
| S-3 · Registration statement | Aug 30, 2024 | Offer document | SEC |
| DEFA14A · Additional proxy material | Aug 28, 2024 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Aug 28, 2024 | Meeting notice | SEC |
| 4 · Change in ownership | Aug 27, 2024 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Aug 26, 2024 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Aug 26, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 23, 2024 | Other filings | SEC |
| 4 · Change in ownership | Aug 22, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 22, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 22, 2024 | Insider trade | SEC |
| PRE 14A · Preliminary proxy statement | Aug 16, 2024 | Meeting notice | SEC |
| 10-Q · Quarterly report | Aug 14, 2024 | Quarterly report | SEC |
| 8-K · Current report | Aug 14, 2024 | Results | SEC |
| D/A | Jun 28, 2024 | Other filings | SEC |
| 4 · Change in ownership | Jun 25, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2024 | Insider trade | SEC |
| SC 13G · Big-stake notice | Jun 10, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Jun 6, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 6, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 6, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 6, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 6, 2024 | Insider trade | SEC |
| 8-K · Current report | May 31, 2024 | Material contract | SEC |
| 424B5 · Prospectus | May 30, 2024 | Offer document | SEC |
| 8-K · Current report | May 30, 2024 | Material contract | SEC |
| 4 · Change in ownership | May 24, 2024 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | May 20, 2024 | Offer document | SEC |
| 10-Q · Quarterly report | May 15, 2024 | Quarterly report | SEC |
| 8-K · Current report | May 15, 2024 | Results | SEC |
| 8-K · Current report | May 13, 2024 | Management or board change | SEC |
| 4 · Change in ownership | Apr 30, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Apr 26, 2024 | Insider trade | SEC |
| D/A | Apr 25, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Apr 24, 2024 | Other filings | SEC |
| 4 · Change in ownership | Apr 10, 2024 | Insider trade | SEC |
| 8-K · Current report | Mar 29, 2024 | Material contract | SEC |
| ARS · Annual report to shareholders | Mar 29, 2024 | Annual report | SEC |
| DEFA14A · Additional proxy material | Mar 28, 2024 | Meeting notice | SEC |
This page holds 200 of 544 filings. Open Filings
Cap table
Built by 6ix from Celcuity Inc.’s releases · as of Oct 29, 2026
- Common shares
- 49,126,314
- Fully diluted
- 49,126,314
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 49,126,314 | Oct 29, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Oct 29, 2026 | 49,126,314 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| David W. Gryska Other companies: Forte Biosciences, Inc. (Director · Since at least Aug 27, 2026); Definium Therapeutics, Inc. (Director · Since at least Jun 11, 2026) | Director · Since at least Oct 1, 2026 |
| Charles R. Romp Other companies: Seagen Inc (EVP, Commercial U.S. · Apr 15, 2020 – Dec 14, 2023 · Past) | Director · Since at least Feb 11, 2026 |
| Polly A. Murphy Other companies: Atea Pharmaceuticals, Inc. (Director · Since at least Mar 26, 2025) | Director · Since at least Jun 24, 2024 |
| Richard J. Nigon Other companies: Northern Technologies International Corporation (Director · Since at least Jul 20, 2026) | Director · Since at least Apr 9, 2026 |
| Brent Eilefson | General Counsel and Chief Compliance Officer · Since at least Nov 5, 2026 |
| Brian Sullivan | Chief Executive Officer & Co-founder · Since at least Aug 18, 2026 |
| Byron Robinson | Chief Strategy Officer · Since at least Nov 5, 2026 |
| David F. Dalvey | Director · Since at least Jun 9, 2026 |
| Eldon Mayer | Chief Commercial Officer · Since at least Nov 5, 2026 |
| Igor Gorbatchevsky | Chief Medical Officer · Since at least Sep 30, 2026 |
All 16 people
| Person | Seat |
|---|---|
| Lance Laing | Chief Science Officer & Co-founder · Since at least Aug 18, 2026 |
| Leo T. Furcht | Director · Since at least May 16, 2019 |
| Maureen Therese Cronin | Director · Sep 19, 2017 – May 16, 2019 · Past |
| Richard E. Buller | Director · Since at least Apr 20, 2022 |
| Vicky Hahne | Chief Financial Officer · Since at least Aug 18, 2026 |
| Vicky Hahne | Chief Financial Officer · Since at least Jul 5, 2018 |
Log in to ask 6ix AI your own questions about Celcuity Inc.